Clinical Trial Update: Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase I, multi-center, open-label dose-escalation study of HuLuc63 in subjects with advanced multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• HuLuc63

Snippet

Sponsor: Facet Biotech | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED